KoBioLabs

KoBioLabs Stock-Based Compensation

The Stock-Based Compensation (SBC) of KoBioLabs (348150.KQ) as of Nov 16, 2026 is 190.70 M KRW. In the previous year, Stock-Based Compensation (SBC) was 265.42 M KRW — a change of -28.15% (lower).

Stock-Based Compensation

190.70 MKRW

YoY

-28.15%

Last updated:

Stock-Based Compensation (SBC) of KoBioLabs is 2025 190.70 M KRW. Stock-Based Compensation (SBC) of KoBioLabs was 2024 265.42 M KRW. It decreases by -28.15% lower compared to the previous year.

The KoBioLabs Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
2.33 B KRW
Jan 1, 2020
2.41 B KRW
Jan 1, 2021
1.72 B KRW
Jan 1, 2022
1.81 B KRW
Jan 1, 2023
800.35 M KRW
Jan 1, 2024
265.42 M KRW
Jan 1, 2025
190.70 M KRW
The KoBioLabs Stock-Based Compensation history
YEARStock-Based CompensationYoY
190.70 MKRW-28.15%
265.42 MKRW-66.84%
800.35 MKRW-55.88%
1.81 BKRW+5.40%
1.72 BKRW-28.44%
2.41 BKRW+3.40%
2.33 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KoBioLabs Stock analysis

What does KoBioLabs do? KoBioLabs Inc., headquartered in Seoul, South Korea, operates in the Health Care sector, specializing in biotechnology. The company focuses on research and development of the microbiome, developing products such as Bioviom and Queens henna FOODOLOGY, as well as new microbiome drugs. It provides commissioned research services and sells its products domestically and internationally. Listed on 18 November 2020, KoBioLabs is active in both domestic and overseas markets. KoBioLabs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KoBioLabs stock

Stock-Based Compensation (SBC) of KoBioLabs is 190.70 M KRW in 2025.

Stock-Based Compensation (SBC) of KoBioLabs changed from 265.42 M KRW to 190.70 M KRW, representing a -28.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) KoBioLabs since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s KoBioLabs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — KoBioLabs

All Key Metrics — KoBioLabs